In the past two decades, there has been concern that levodopa—the gold-standard therapy for Parkinson disease (PD)—may be toxic to dopaminergic neurons. However, findings from a recent study suggest that chronic use of levodopa does not enhance progression of PD pathology. Can we make sense of this controversy?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spencer, J. P. et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic. Res. 24, 95–105 (1996).
Murer, M. G. et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43, 561–575 (1998).
Shin, J. Y., Park, H. J., Ahn, Y. H. & Lee, P. H. Neuroprotective effect of L-DOPA on dopaminergic neurons is comparable to pramipexole in MPTP-treated animal model of Parkinson's disease: a direct comparison study. J. Neurochem. 111, 1042–1050 (2009).
Parkkinen, L. et al. Does levodopa accelerate the pathologic process in Parkinson disease brain. Neurology 77, 1420–1426 (2011).
Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (Suppl. 3), S26–S38 (2003).
Olanow, C. W., Gauger, L. L. & Cedarbaum, J. M. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann. Neurol. 29, 556–559 (1991).
Fahn, S. et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498–2508 (2004).
Rascol, O. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342, 1484–1491 (2000).
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284, 1931–1938 (2000).
Constantinescu, R., Romer, M., McDermott, M. P., Kamp, C. & Kieburtz, K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov. Disord. 22. 1317–1319 (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Zesiewicz, T. The controversy of levodopa toxicity in Parkinson disease. Nat Rev Neurol 8, 8–10 (2012). https://doi.org/10.1038/nrneurol.2011.199
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.199
This article is cited by
-
Wo stehen wir nach 100 Jahren mit L-Dopa?
DNP - Der Neurologe und Psychiater (2012)
